Physician profile
Amarinder S Bindra
NPI 1528218286
$512,382.62
in general payments reported to CMS, 2019-2025
23 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $55K · 2021: $92K · 2022: $120K · 2023: $23K · 2024: $43K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K · Travel and Lodging: $13K · Food and Beverage: $8,241 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,625.00 |
| Travel and Lodging | $13,051.17 |
| Food and Beverage | $8,241.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,604.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $132,257.66 | 2019-2025 | Jardiance |
| Pfizer INC. | $113,084.15 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $101,258.11 | 2021-2025 | Verquvo |
| Cvrx, INC. | $82,744.61 | 2022-2025 | Barostim Neo System |
| Lilly USA, LLC | $60,024.16 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $12,226.36 | 2019-2025 | |
| Novo Nordisk INC | $3,994.64 | 2021-2024 | Ozempic |
| Impulse Dynamics (USA) INC. | $2,288.65 | 2021-2022 | |
| Abbott Laboratories | $1,169.42 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Akcea Therapeutics, INC. | $946.00 | 2020 | |
| Amgen INC. | $937.44 | 2019 | |
| Abiomed | $456.47 | 2021-2025 | Impella |
| Zoll Respicardia, INC. | $314.44 | 2023 | Remede System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $265.22 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $211.15 | 2022-2024 | Eliquis, Camzyos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $46.69 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $42.61 | 2023-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $34.95 | 2023-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $31.82 | 2021-2024 | |
| Nuwellis, INC. | $19.66 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $16.79 | 2019 | |
| Abbvie INC. | $11.62 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarinder Bindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.